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Abstract  
 
Purpose: This phase III, non-blinded, parallel-group, randomised controlled study 
evaluated the efficacy of Caphosol mouthwash in the management of radiation-
induced oral mucositis (OM) in patients with head and neck cancer (HNC) 
undergoing radical (chemo)radiotherapy.  
 
Patients and Methods: Eligible patients were randomised at 1:1 to Caphosol plus 
standard oral care (intervention) or standard oral care alone (control), stratified by 
radiotherapy technique and use of concomitant chemotherapy. Patients in the 
intervention arm used Caphosol for 7 weeks: 6 weeks during and 1-week post-
radiotherapy. The primary endpoint was the incidence of severe OM (CTCAE ≥grade 
3) during and up to week 8 post-radiotherapy. Secondary endpoints include 
pharyngeal mucositis, dysphagia, pain and quality of life.  
Results: The intervention (n=108) and control (n=107) arms were well balanced in 
terms of patient demographics and treatment characteristics. Following exclusion of 
patients with missing data, 210 patients were available for primary analysis. The 
incidence of severe OM did not differ between the intervention and control arms 
(64.1% versus 65.4%, p=0.839). There was also no significant benefit observed with 
Caphosol for other secondary endpoints.  
Conclusion: Caphosol did not reduce the incidence or duration of severe OM during 
and after radiotherapy in HNC.  
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Introduction 
 
Radical radiotherapy with concomitant chemotherapy is the standard of care for 
treatment of locally advanced head and neck cancer (HNC). Despite advances in 
computational technology and innovations in radiotherapy planning, treatment-
related acute toxicity remains considerable. 
 
Oral mucositis (OM) is a well-recognised acute toxicity of head and neck 
radiotherapy. OM often causes pain and dysphagia, leading to weight loss and 
malnutrition [1]. More importantly, poorly managed OM may lead to treatment 
interruptions, which are detrimental to treatment outcome [2,3]. A systematic review 
of 33 studies demonstrated that 34% patients with HNC receiving radical 
radiotherapy will develop severe (grade 3 or more) OM and the risk increases further 
to 43% for those receiving concomitant chemotherapy [2]. Patients with cancers of 
oral cavity and oropharynx are at the highest risk, as well as those receiving altered 
fractionation regimens [4,5]. 
The process leading to the development of mucositis is complex. The sequence of 
biological events is initiated by the production of reactive oxygen species which 
cause DNA strand breaks [6]. These, in turn, not only cause clonogenic death of the 
basal stem cells, but also trigger the transduction pathways resulting in activation of 
several transcription factors that lead to expression of several pro-inflammatory 
cytokines [6]. Despite better understanding of these processes, the standard-of-care 
management in patients with radiation-induced mucositis has not changed for many 
years and this unpleasant condition continues to pose a therapeutic challenge.   
 
Caphosol is an aqueous solution of concentrated calcium phosphate, which is 
licensed for use in conditions resulting in dryness of the mouth and throat. As its 
composition is similar to natural saliva, it is postulated that it could help to maintain 
healthy oral mucous membranes during treatment by modulating the inflammatory 
process and promoting tissue repair [7]. Whilst its effectiveness has been 
documented for patients with haematological malignancies undergoing high dose 
chemotherapy [7,8], the role of Caphosol in radiation-induced OM in HNC is less 
clear with conflicting results in the literature [9].  To date, most studies of Caphosol in 
HNC were retrospective and even if prospective, were single-arm.  
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Here, we report the result of the first prospective phase III randomised controlled trial 
on the efficacy of Caphosol mouthwash in the management of radiation-induced OM 
in HNC. 
 
Material and methods 
 
Study design and participants 
 
This was a single institution, phase III, non-blinded, randomised controlled trial 
conducted at the Royal Marsden Hospital between December 2011 and January 
2015. This study received approvals from the local clinical research and research 
ethical committee (CCR3571, REC no. 11/EE/0044).  
Eligible participants were patients with any histologically proven carcinoma of the 
head and neck (except thyroid and larynx), aged 18 years or above, receiving 
(chemo)radiotherapy in a radical setting with Karnofsky’s performance status >70%. 
The use of induction chemotherapy was permitted. Exclusion criteria included 
inability to use mouthwash, any previous radiotherapy to the head and neck region 
and mucosal ulceration at baseline (either post-surgery or post-induction 
chemotherapy).  
 
All patients were treated with conventional fractionation (5 fractions every week). 
Both 3D-conformal and intensity-modulated radiotherapy (IMRT) techniques were 
allowed. Radiotherapy dose-fractionation were delivered as per institutional protocol: 
for primary treatment, macroscopic and microscopic disease were treated with 65 Gy 
and 54 Gy in 30 fractions, respectively, whereas for adjuvant radiotherapy, the post-
operative surgical bed was treated with 60 Gy in 30 fractions, provided that there was 
no residual macroscopic tumour. As a general rule, tumours at or approaching 
midline received bilateral neck irradiation. Radiation protocol violations, such as 
treatment breaks greater than 1 week and failure to complete treatment, were 
recorded.   
Concomitant platinum-based chemotherapy or cetuximab were permissible in this 
study. Typical systemic therapy regimens included cisplatin 100 mg/m2 or carboplatin 
AUC 5 on day 1 and 29 and cetuximab 400 mg/m2 loading dose prior to radiotherapy 
with weekly maintenance dose 250 mg/m2. The choice of systemic therapy was at 
the discretion of the attending physician.  
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Study end points 
 
The primary efficacy measure for this study was the incidence of severe (grade 3 or 
more) OM during and eight weeks after completion of (chemo) radiotherapy. We 
hypothesised that the use of Caphosol would lead to reduced incidence of severe 
OM compared to standard oral care alone. Other secondary efficacy measures 
included: a) the duration of severe OM; b) the incidence and duration of severe 
pharyngeal mucositis (PM); c) the incidence and duration of severe dysphagia; d) the 
incidence and duration of severe radiation-induced pain; and e) patients reported 
quality of life (QoL).  
 
Randomisation and trial interventions 
 
Prior to starting (chemo) radiotherapy, recruited patients were randomised (1:1) to 
the use of standard oral care regimen (control) or Caphosol plus standard oral care 
(intervention). Randomisation was performed by the Clinical Trials and Statistics Unit 
(CTSU) at The Institute of Cancer Research (ICR) using random permuted blocks 
method. Patients were stratified by radiotherapy technique (unilateral versus 
bilateral) and type of therapy (chemoradiotherapy versus radiotherapy only).  
The patients in the intervention arm started using Caphosol from the first week of 
radiotherapy. Caphosol was used as a mouthwash 4 times a day but the frequency 
could be increased up to 10 times a day at the physician’s or patient’s discretion. 
Patients used Caphosol for a total duration of 7 weeks; 6 weeks during radiotherapy 
and 1 week after completion. Depending on the symptoms, patients had access to 
other symptom control measures available in the control arm. If patients did not 
tolerate Caphosol, it could be stopped immediately and the reasons for 
discontinuation were recorded.  
Patients in the control arm received standard treatment for OM. At our institution, this 
included normal saline mouthwash at least 4 times a day, aspirin mouthwash 3 times 
a day and tooth brushing with fluoride toothpastes prescribed by a dental hygienist. 
All patients were prescribed analgesia according to the WHO analgesic ladder [10] 
and topical anaesthetics, such as lidocaine gel. Anti-fungal or anti-viral therapy were 
also prescribed when necessary. 
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Evaluation and data collection 
 
All trial evaluation data were collected prospectively during clinic visits. Baseline 
assessments included head and neck examination, nutritional status, pain relief 
requirements, smoking status, alcohol and recreational drugs use. Patients were 
assessed on a weekly basis during and up to 4 weeks following completion of 
radiotherapy. The final assessment fell on week 8 post-radiotherapy.   
 
The scoring of radiation-induced side effects was performed objectively by trained 
physicians according to the NCI Common Toxicity Criteria scoring system (CTCAE) 
version 4.0. QoL was assessed using the EORTC quality of life questionnaire, QLQ-
C30 version 3.0 and QLQ-HN35 at the following time points: pre-radiotherapy, week 
4 during radiotherapy, week 4 and 8 post-completion of radiotherapy.  
 
Sample size  
 
The primary objective of the study was to determine whether the difference in the 
rate of severe OM in the intervention and control groups was at least 20%. We 
assumed that the proportion of patients with severe OM would be 20% and 40% in 
the intervention and control groups, respectively. A two group chi-squared test with a 
0.05 two-sided significance level had 90% power to detect the difference between a 
Group 1 proportion (intervention arm), π1, of 0.20 and a Group 2 proportion (control 
arm), π2, of 0.40 when the sample size in each group was 109. Therefore, the 
calculated sample size required to detect a difference of at least 20% in the 
proportion of severe OM between the two arms with 90% power was 218 patients.  
 
Analytical statistics 
The data were analysed using STATA statistical software (Version 13.1; StataCorp 
LP, Texas, USA). Descriptive statistics were used to summarise patient baseline 
characteristics. All quantitative data were reported as mean and standard deviation. 
If the data were not normally distributed, median was used together with interquartile 
range. Qualitative data were presented as number of observations and percentages. 
All missing data were recorded.  
 
The primary analysis was performed based on treatment actually received (‘as 
treated’) and included all patients who received at least one week of Caphosol 
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mouthwash treatment. Patients with missing outcome data for more than two 
consecutive visits were also excluded. The proportion of patients with severe (grade 
3 or more) OM at any point during radiotherapy or 8 weeks after was compared 
between the two treatment groups using the Chi-Squared test. The level of 
significance was set at p<0.05. The mean duration of severe OM was recorded for 
patients in days. The Mann-Whitney U test was used to compare the duration of 
severe OM between the intervention and control groups. The same analyses were 
repeated for other secondary endpoints: PM, dysphagia and pain.  
For QoL data analysis, the global score and sub-scores associated with oral 
symptoms were summarised and presented graphically. Changes from baseline 
measurements (%) at each time point were plotted and the differences between the 
two arms were visually inspected with 95% confidence interval (CI). If a separation 
was apparent with no or minimal overlap in 95% CI, Mann-Whitney U test was used 
for further analysis. Comparisons for QoL were tested at a significance level of 1% to 
allow for multiple endpoints. 
 
Results 
 
Study population 
 
This study achieved its accrual target: 220 patients were recruited and randomised. 
Following exclusion of 5 patients who either were ineligible or withdrew at the start, 
215 patients (108 in the intervention arm and 107 in the control arm) continued with 
the study (figure 1). There were two allocation errors, where one patient randomised 
to each arm ended up receiving treatment in the opposite arm.  
 
Baseline patient demographics and clinical characteristics were similar in both 
groups (table 1). The only exception was that there was a higher proportion of 
patients with oral cavity and oropharyngeal carcinomas in the intervention arm (75.9% 
versus 63.3%). The treatment characteristics were well balanced between the two 
groups following stratifications by type of therapy (chemoradiotherapy versus 
radiotherapy alone) and radiotherapy technique (unilateral versus bilateral) (table 2). 
However, a higher number of patients underwent induction chemotherapy prior to 
radiotherapy in the control arm (46.7% versus 36.1%).  
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Caphosol usage 
 
The percentage of patients using Caphosol at least 4 times a day decreased with 
each week of radiotherapy (figure 2). In the first week of radiotherapy, 80% (84/105) 
of patients used Caphosol regularly but this gradually decreased to 55.2% (58/105) 
by week 7. The main reason for stopping Caphosol was treatment-induced nausea. 
Other less common reasons included oral irritation or pain, intolerable taste and 
perceived lack of benefit. There was no serious adverse event reported with 
Caphosol.  
 
Primary endpoint 
 
Patients had to have used Caphosol for at least one week to be included in the ‘as 
treated’ analysis. Excluding patients with inadequate or missing data, 103 patients in 
the intervention arm and 107 in the control arm were available for analysis. There 
was no difference in the incidence of severe OM between the intervention and 
control groups (64.1% versus 65.4% respectively, p=0.839). The incidences of 
maximum grade of OM for both groups are shown in appendix 1. 
 
A subgroup analysis was also performed in the group with the highest risk of severe 
OM i.e. patients with oral cavity and oropharyngeal primary tumours. In this subgroup, 
the intervention arm had a lower occurrence of severe OM compared to the control 
arm but this did not reach statistical significance (61.3% [49/80] versus 72.1% [49/68] 
respectively, p=0.222).  
 
Secondary endpoints 
 
The duration of severe OM did not differ between the intervention and control arms: 
16.8±17.5 vs. 17.5±21.9 days, respectively (p=0.692). Whilst the intervention arm 
showed a lower incidence and shorter duration of other measured radiation-induced 
toxicities (PM, dysphagia and pain), none of these reached statistical significance 
(p>0.05, table 3). 
 
The response rate to QoL questionnaires was low, but similar between the two arms. 
QLQ-C30 response rate rates for the four time points, from pre-radiotherapy to week 
8 post-radiotherapy, were 54.2%, 34.6%, 41.1% and 35.5% for the control arm and 
59.2%, 37.9%, 39.8% and 36.9% for the intervention arm, respectively. The 
 9 
corresponding response rates for QLQ-HN35 were 54.2%, 35.5%, 41.1% and 34.6% 
for the control arm and 57.3%, 38.8%, 40.8% and 34.0% for the intervention arm, 
respectively.  
 
The pre-radiotherapy mean global health status (GHS) score and functional sub-
scores measured by QLQ-C30 were identical in both arms (appendix 2). There was 
no difference between the two groups in the changes from pre-radiotherapy scores 
for GHS and functional scales at all time points (figure 3). Similarly, there was no 
difference between the two groups in the head and neck specific symptoms rated by 
patients through QLQ-HN35 (figure 4). However, it was noteworthy that more 
patients in the control arm were still reliant on feeding tube at week 8 post-
radiotherapy compared to the intervention arm, even though it did not reach 
statistical significance (p=0.011).  
 
Discussion 
 
We conducted the largest randomised study to date, to evaluate the efficacy of 
Caphosol in radiation-induced mucositis in patients with HNC undergoing radical 
(chemo) radiotherapy. Our data did not demonstrate any benefit from Caphosol in 
either reducing the incidence or shortening the duration of severe OM. Caphosol also 
did not provide any significant improvement in other associated acute toxicities in 
comparison to standard oral care. Our results, therefore, confirm findings from 
previous smaller studies that Caphosol does not have a significant role in managing 
radiation-induced acute mucositis in HNC [11-13]. 
 
A previous study by Rao et al reported self-assessed improvement of pain, 
swallowing and eating scores with Caphosol in approximately 50% of patients [12]. 
However, the study did not have a control group to determine if it was truly the effect 
of Caphosol above other topical anaesthetics used. We also addressed this issue in 
this study but found no significant improvement in the QoL reported by patients in the 
intervention arm. Nevertheless, one observation in our study is that fewer patients in 
the intervention arm were dependent on a feeding tube by week 8 post-radiotherapy, 
albeit statistically non-significant. Whilst this may imply that Caphosol aids the speed 
of recovery from acute toxicity, it needs to be interpreted with caution given the fact 
that the data only represent a smaller subgroup of patients (~40%). Moreover, there 
are likely to be other contributing variables such as personal motivation, fear of 
eating or level of malnourishment, which were not recorded or accounted for. 
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It is widely acknowledged that there is a general issue with compliance with self-
administered agents for prevention and treatment of mucositis. We found a similar 
pattern with 20% of patients not using Caphosol regularly, even in the first week of 
radiotherapy. This was due to a small subgroup of patients who either found it 
intolerable due to taste (partly precipitated by altered taste sensation secondary to 
treatment) or perceived lack of need for usage at an early stage during radiotherapy. 
The gradual decrease in its usage with each week of radiotherapy coincides with the 
onset of OM, at which point some patients found the mouthwash difficult to tolerate. 
 
The contrast between our results and those in patients with haematological 
malignancies are likely to reflect the different treatments received by the two groups. 
The longer interval between administration of chemotherapy in this setting, allows 
more time for the oral mucosa to recover. On the contrary, with daily, fractionated 
radiotherapy, the insults are continuous, resulting in cumulative injury with little time 
for tissue repair. It is interesting to note that in the haematological studies, Caphosol 
was administered by trained nurses, which, invariably improved compliance but this 
is not a practicable solution for patients who receive radiotherapy as outpatients.  
 
Apart from Caphosol, numerous other mucositis agents have been tested in head 
and neck radiotherapy. So far, only palifermin, a recombinant keratinocyte growth 
factor, has been consistently shown to significantly reduce the severity and duration 
of radiation-induced mucositis in HNC [14,15]. The disappointment, however, is that 
the benefit in physician-assessed OM did not translate into better patient-reported 
outcomes or reduced radiotherapy breaks. Of note, the incidences of treatment 
breaks in both arms of our study were identical (table 2) and significantly lower than 
those reported in palifermin studies (4-5% versus 14-15%). This suggests that whilst 
the incidence of severe OM remained considerable, our current standard oral care 
regimen provided adequate support for patients to complete their planned treatment.  
 
As there is a clear dose response association for developing severe OM: 50% 
probability at 51 Gy [16], it is challenging to elicit any additional clinically relevant 
benefit with anti-mucositis agents alone without radiotherapy dose or volume 
modifications.  Continued efforts to better define target volumes with adaptation 
during radiotherapy based on image defined response, are required to reduce the 
volume of normal tissue within the radiation field, thereby reducing rates of toxicity 
whilst maintaining cure rates. Novel oral mucosal surface delineation [17], functional 
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imaging-guided target delineation and treatment adaptation [18,19] are areas of 
ongoing research.    
 
We acknowledge that our study has several limitations. As an open label, non-
placebo controlled trial, there was no blinding of the physicians assessing the 
patients and this may have introduced biases. This may have also influenced the 
way patients completed their QoL questionnaires. There were significant challenges 
with manufacturing identically-packaged placebo. Second, whilst our patients were 
stratified by radiotherapy technique and type of therapy, they were not further 
stratified by primary site of disease. Consequently, there was a small difference in 
the distribution of high-risk patients between the two groups. Finally, even though we 
did not expect a high response rate for QoL questionnaires, the rate was significantly 
lower than originally projected. This may have been related to the relatively long 
questionnaires, which some patients found ‘laborious’ and the presence of acute 
toxicities, especially during the latter part of radiotherapy.  
Conclusion 
 
Caphosol did not reduce the incidence or duration of severe OM during and after 
radiotherapy in HNC.  
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Figure legends 
 
Figure 1. Consort diagram of this study.  
 
Figure 2. Histogram showing percentage of patients using Caphosol at least 4 times 
a day at weekly intervals during and 1-week post-radiotherapy (n = 105).  
 
Figure 3. Graphical presentations of mean changes (%) at each time point relative to 
pre-radiotherapy score for core function scales of QLQ-C30 (A – Global health 
status; B – Physical functioning; C – Social functioning; D – Role Functioning; and E 
– Emotional functioning).  
 
Figure 4. Graphical presentations of mean changes (%) at each time point relative to 
pre-radiotherapy score for QLQ-HN35 components associated with oral symptoms  
(A – Swallowing; B – Pain; C – Senses problems; D – Sticky saliva; E – Feeding 
tube; F – Weight loss; G – Nutritional Supplement use; and H – Dry mouth).  
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Appendix 2: Summary of core scales (QLQ-C30) including counts and mean changes from pre-treatment scores with 95% confidence intervals 
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-18.9 
(-31.0,  -6.8) 
44 
-26.9 
(-38.6, -15.2) 
38 
-17.5 
(-29.4,  -5.7) 
61 79.5 39 
-30.3 
(-41.0, -19.7) 
41 
-26.4 
(-39.0, -13.9) 
38 
-23.7 
(-33.9, -13.5) 
Emotional 
functioning 
58 83.6 37 
-9.2 
(-16.1,  -2.3) 
44 
-6.6 
(-13.5,   0.2) 
38 
-13.9 
(-22.9,  -4.9) 
61 75.3 39 
-1.5 
(-6.2,   3.2) 
41 
-1.2 
(-7.1,   4.6) 
37 
0.7 
(-4.3,   5.7) 
Cognitive 
functioning 
58 84.8 37 
-16.2 
(-24.1,  -8.2) 
44 
-6.4 
(-11.7,  -1.2) 
38 
-9.6 
(-17.2,  -2.1) 
61 79.0 39 
-10.7 
(-16.5,  -4.8) 
41 
-2.0 
(-8.5,   4.4) 
37 
-2.3 
(-8.8,   4.3) 
Social functioning 58 75.6 37 
-18.5 
(-27.6,  -9.3) 
44 
-22.7 
(-31.6, -13.9) 
38 
-17.5 
(-27.4,  -7.7) 
61 74.6 39 
-15.8 
(-23.8,  -7.9) 
41 
-15.4 
(-23.4,  -7.5) 
37 
-9.0 
(-17.0,  -1.0) 
Fatigue 58 28.7 37 
26.1 
(17.1,  35.0) 
43 
22.1 
(12.2,  32.0) 
38 
19.0 
( 9.7,  28.3) 
61 28.2 39 
28.7 
(19.9,  37.5) 
41 
21.4 
(13.2,  29.6) 
38 
21.6 
(12.9,  30.3) 
Nausea and 
vomiting 
58 8.9 37 
24.8 
(15.7,  33.9) 
44 
8.3 
( 0.8,  15.9) 
38 
10.5 
( 1.9,  19.2) 
61 7.1 39 
29.5 
(21.4,  37.6) 
41 
11.8 
( 6.4,  17.2) 
38 
10.5 
( 2.8,  18.3) 
Pain 58 20.4 37 
27.0 
(16.8,  37.1) 
44 
15.9 
( 6.4,  25.5) 
38 
8.3 
( 1.0,  15.7) 
61 21.3 39 
25.7 
(15.3,  36.1) 
41 
8.5 
( 1.1,  15.9) 
38 
12.7 
( 4.6,  20.8) 
Dyspnoea 58 6.9 37 
8.1 
( 0.8,  15.4) 
44 
9.8 
( 3.6,  16.1) 
38 
10.5 
( 2.0,  19.1) 
61 13.1 39 
5.1 
(-3.0,  13.2) 
41 
11.4 
( 4.0,  18.8) 
38 
7.0 
( 1.4,  12.6) 
Insomnia 58 30.5 36 
2.8 
(-6.0,  11.5) 
44 
4.5 
(-6.0,  15.1) 
38 
1.8 
(-11.5,  15.0) 
61 35.5 39 
-2.5 
(-15.1,  10.0) 
41 
-1.6 
(-11.3,   8.0) 
38 
5.3 
(-7.2,  17.7) 
Appetite loss 57 18.7 36 
55.6 
(41.5,  69.6) 
43 
40.3 
(28.5,  52.1) 
37 
22.5 
( 9.1,  35.9) 
61 24.6 37 
47.8 
(35.8,  59.8) 
40 
24.2 
( 9.6,  38.8) 
38 
23.7 
(10.2,  37.2) 
Constipation 58 20.1 37 
14.4 
( 1.1,  27.7) 
44 
9.8 
( 0.4,  19.2) 
38 
7.0 
(-4.8,  18.9) 
61 24.6 39 
27.3 
(17.4,  37.2) 
41 
17.1 
( 5.9,  28.3) 
38 
1.8 
(-9.8,  13.3) 
Diarrhoea 57 4.7 37 
9.0 
( 1.6,  16.4) 
43 
-0.8 
(-4.8,   3.3) 
37 
0.9 
(-6.9,   8.7) 
61 6.0 39 
3.4 
(-4.5,  11.3) 
41 
4.1 
(-1.1,   9.3) 
36 
7.4 
(-1.7,  16.5) 
Financial difficulties 58 21.8 37 
-0.0 
(-7.6,   7.5) 
43 
2.3 
(-5.6,  10.3) 
38 
3.5 
(-6.0,  13.0) 
61 24.0 39 
0.8 
(-6.1,   7.8) 
41 
2.4 
(-5.9,  10.8) 
37 
7.2 
(-0.0,  14.4) 
Appendix 3: Summary of Head & Neck scales (QLQ-H&N35) including counts and mean changes of scores from pre-treatment levels with 95% confidence intervals 
QLQ-
HN35 
Standard oral care Caphosol 
C
o
u
n
t 
M
ea
n
 a
t 
P
re
-R
T 
Change from Pre-RT (95%CI) 
C
o
u
n
t 
M
ea
n
 a
t 
P
re
-R
T 
Change from Pre-RT (95%CI) 
C
o
u
n
t 
4 weeks during 
RT C
o
u
n
t 
4 weeks post RT 
C
o
u
n
t 
8 weeks post RT 
C
o
u
n
t 
4 weeks during 
RT C
o
u
n
t 
4 weeks post RT 
C
o
u
n
t 
8 weeks post RT 
Pain 58 20.4 38 
33.6 
(24.5,  42.6 ) 
44 
22.0 
(13.1,  30.8 ) 
36 
20.1 
(10.7,  29.4 ) 59 
22.6 40 
36.5 
(28.8,  44.1 ) 
41 
19.3 
(10.2,  28.4 ) 
35 
12.6 
(4.5,  20.7) 
Swallowing 58 13.4 38 
40.3 
(30.2,  50.4 ) 
44 
21.1 
(12.2,  30.1 ) 
36 
20.4 
(10.9,  29.9 ) 59 
14.9 39 
33.4 
(24.1,  42.6 ) 
40 
17.4 
(9.1,  25.6 ) 
35 
16.2 
(8.3,  24.1) 
Senses problems 58 12.4 38 
47.4 
(35.8,  59.0 ) 
44 
33.0 
(26.1,  39.8 ) 
36 
28.7 
(19.4,  38.1 ) 59 
12.7 40 
42.5 
(33.6,  51.5 ) 
41 
22.4 
(12.8,  31.9 ) 
35 
24.8 
(16.7,  32.8) 
Speech problems 58 11.9 36 
29.0 
(20.3,  37.8 ) 
43 
19.4 
(11.1,  27.7 ) 
37 
17.3 
(8.1,  26.4 ) 58 
14.2 40 
25.2 
(16.9,  33.5 ) 
42 
12.4 
(6.8,  18.1 ) 
35 
18.4 
(11.1,  25.8) 
Trouble with social 
eating 
58 13.9 37 
54.0 
(43.5,  64.5 ) 
42 
35.4 
(25.0,  45.9 ) 
37 
36.6 
(25.2,  47.9 ) 57 
16.3 39 
42.9 
(32.6,  53.3 ) 
41 
30.9 
(21.2,  40.5 ) 
34 
27.2 
(17.0,  37.4) 
Trouble with social 
contact 
57 6.9 37 
18.9 
(9.7,  28.1 ) 
43 
16.1 
(9.4,  22.7 ) 
37 
10.9 
(3.4,  18.5 ) 58 
9.5 40 
8.6 
(3.1,  14.0 ) 
42 
9.5 
(4.0,  15.0 ) 
35 
8.8 
(2.7,  14.8) 
Less sexuality 56 22.6 36 
41.6 
(28.7,  54.5 ) 
39 
39.7 
(27.6,  51.8 ) 
33 
32.3 
(20.1,  44.5 ) 55 
34.2 37 
23.4 
(11.4,  35.4 ) 
38 
18.4 
(5.0,  31.8 ) 
34 
19.1 
(7.8,  30.4) 
Teeth 58 17.2 37 
0.0 
(-9.4,   9.5 ) 
44 
-0.0 
(-11.2,  11.2 ) 
34 
4.9 
(-9.7,  19.5 ) 58 
17.8 40 
-2.5 
(-10.4,   5.4 ) 
41 
1.6 
(-7.8,  11.0 ) 
35 
1.9 
(-6.1,   9.9) 
Opening mouth 57 19.9 38 
18.3 
(8.3,  28.4 ) 
44 
17.4 
(8.3,  26.6 ) 
35 
12.4 
(-1.0,  25.8 ) 59 
15.8 40 
23.3 
(9.8,  36.7 ) 
41 
21.1 
(12.4,  29.9 ) 
35 
17.1 
(7.3,  26.9) 
Dry mouth 58 22.4 38 
44.7 
(32.3,  57.1 ) 
44 
43.2 
(33.3,  53.0 ) 
36 
51.9 
(39.0,  64.7 ) 59 
22.6 40 
40.8 
(30.0,  51.7 ) 
40 
30.8 
(21.1,  40.6 ) 
35 
47.6 
(33.9,  61.4) 
Sticky saliva 58 19.0 38 
61.4 
(50.5,  72.4 ) 
44 
43.2 
(32.7,  53.7 ) 
36 
38.9 
(23.4,  54.4 ) 59 
23.7 40 
51.7 
(39.7,  63.6 ) 
41 
26.0 
(14.3,  37.8 ) 
35 
40.0 
(25.9,  54.1) 
Coughing 58 19.5 37 
24.3 
(13.6,  34.9 ) 
44 
19.7 
(9.0,  30.4 ) 
35 
13.3 
(2.6,  24.1 ) 59 
22.6 40 
19.9 
(11.2,  28.6 ) 
41 
13.8 
(5.3,  22.4 ) 
35 
6.7 
(-2.5,  15.9) 
Felt ill 57 13.5 37 
36.1 
(26.1,  46.0 ) 
43 
8.5 
(-0.2,  17.2 ) 
35 
9.5 
(1.7,  17.4 ) 59 
13.0 40 
29.9 
(20.0,  39.8 ) 
41 
13.0 
(4.8,  21.2 ) 
35 
11.4 
(3.0,  19.9) 
Pain killers 56 55.4 36 
38.9 
(20.9,  56.8 ) 
41 
19.5 
(-0.1,  39.1 ) 
36 
13.9 
(-5.5,  33.3 ) 58 
46.6 40 
57.5 
(42.0,  73.0 ) 
42 
40.5 
(22.7,  58.2 ) 
35 
28.6 
(9.6,  47.5) 
Nutritional 
supplement 
57 24.6 37 
54.1 
(36.1,  72.0 ) 
43 
48.8 
(28.9,  68.8 ) 
35 
37.1 
(14.3,  60.0 ) 58 
29.3 40 
50.0 
(34.3,  65.7 ) 
41 
39.0 
(19.8,  58.2 ) 
35 
48.6 
(29.9,  67.2) 
Feeding tube 57 3.5 37 
8.1 
(-0.8,  17.0 ) 
43 
27.9 
(14.3,  41.5 ) 
37 
21.6 
(8.2,  35.1 ) 58 
8.6 40 
7.5 
(-3.3,  18.3 ) 
41 
19.5 
(5.5,  33.6 ) 
35 
0.0 
(-8.0,   8.0) 
Weight loss 56 21.4 36 
66.7 
(51.0,  82.3 ) 
35 
28.6 
(8.0,  49.2 ) 
33 
24.2 
(0.1,  48.4 ) 55 
21.8 38 
55.3 
(34.8,  75.8 ) 
39 
23.1 
(3.4,  42.7 ) 
33 
45.5 
(26.2,  64.7) 
 
Table 1. Patient demographics 
Characteristics 
Caphosol plus SC 
 (n = 108) 
Standard care (SC)  
(n = 107) 
All patients 
(N = 215) 
 No. % No. % No. % 
Sex       
  Female 23 21.3 31 29.0 54 25.1 
  Male 85 78.7 76 71.0 161 74.9 
       
Age (years)       
  Mean (SD) 57.8 (11.7) 59.9 (9.3) 58.8 (10.6) 
       
Primary sites       
  Oral cavity 15 13.9 11 10.3 26 12.1 
  Oropharynx 67 62.0 57 53.3 124 57.6 
  Nasopharynx/Sinonasal 3 2.8 8 7.5 11 5.1 
  Hypopharynx 3 2.8 9 8.4 12 5.6 
  Unknown primary 9 8.3 12 11.2 21 9.8 
  Salivary glands 10 9.3 8 7.5 18 8.4 
  Others† 1 0.9 2 1.8 3 1.4 
       
Tumour stage (AJCC)       
  I 8 7.4 5 4.7 13 6.0 
  II 13 12.0 13 12.1 26 12.1 
  III 18 16.7 9 8.4 27 12.6 
  IV 69 63.9 80 74.8 149 69.3 
       
Histology       
  SCC 97 89.8 98 91.6 195 90.7 
  Others* 11 10.2 9 8.4 20 9.3 
       
Weight loss (kg)       
  Mean (SD) 0.7 (2.1) 0.6 (2.1) 0.6 (2.1) 
       
Pain relief       
  No 73 67.6 77 72.0 150 69.8 
  Yes 35 32.4 30 28.0 65 30.2 
       
Smoker       
  No 87 80.6 89 83.2 176 81.9 
  Yes 21 19.4 18 16.8 39 18.1 
       
Alcohol       
  No 38 35.2 41 38.3 79 36.7 
  Yes 70 64.8 66 61.7 136 63.3 
       
Recreational drug use       
  No 104 96.3 105 98.1 209 97.2 
  Yes 4 3.7 2 1.9 6 2.8 
       
† Include skin and orbital tumour 
* Include adenocarcinoma, small cell, acinic cell, mucoepidermoid and adenoid cystic  
   carcinoma  
Table 2. Study treatment  
Treatment 
 
Caphosol plus  
SC 
 (n = 108) 
Standard care  
(SC) 
(n = 107) 
All patients 
 
(N = 215) 
 No. % No. % No. % 
Radiotherapy       
RT only 44 40.7 39 36.4 83 38.6 
CRT                  
 
 
Carboplatin 22 20.3 31 29.0 53 24.7 
Cetuximab 2 1.9 0 0 2 0.9 
Cisplatin 31 28.7 30 28.0 61 28.4 
Cis/Carbo* 9 8.4 7 6.6 16 7.4 
Total 64 59.3 68 63.6 132 61.4 
       
Induction chemotherapy       
No 69 63.9 57 53.3 126 58.6 
Yes 
 
 
Carbo/5FU 10 9.3 9 8.4 19 8.8 
Cis/5FU 27 25.0 36 33.6 63 29.3 
Cis/5FU & 
Carbo/5FU 2 1.8 5 4.7 7 3.3 
Total 39 36.1 50 46.7 89 41.4 
       
Technique    
Bilateral 80 74.1 77 72.0 157 73.0 
Unilateral 28 25.9 30 28.0 58 27.0 
       
Technique       
3D-Conformal 13 12.0 7 6.5 20 9.3 
IMRT 95 88.0 100 93.5 195 90.7 
       
RT breaks       
No 104 96.3 102 95.3 206 95.8 
Yes 4 3.7 5 4.7 9 4.2 
       
 
*Cisplatin Day 1 switched to carboplatin Day 29 
  
Table 3. Efficacy end points (as treated analysis). 
 
End points 
Caphosol plus SC 
(n = 103) 
Standard care (SC) 
(n = 107) 
 
p value 
 No. % No. %  
Primary      
  Incidence of ≥G3 OM 66 64.1 70 65.4 0.839 
      
Secondary      
Duration of ≥G3 OM (days)      
           Mean (SD) 16.8 (17.5) 17.5 (21.9) 0.692 
      
  Incidence of ≥G3 PM 59 57.3 68 64.2 0.309 
Duration of ≥G3 PM (days)      
           Mean (SD) 13.7 (16.7) 18.4 (21.5) 0.187 
      
   Incidence of ≥G3 PD 30 29.1 33 31.1 0.752 
   Duration of ≥G3 PD (days)      
           Mean (SD) 8.3 (16.7) 9.7 (19.5) 0.671 
      
    Incidence of ≥G3 pain  50 48.5 58 54.7 0.372 
    Duration of ≥G3 pain      
           Mean (SD) 18 (24.7) 20 (24.1) 0.397 
      
 
OM – oral mucositis, PM – pharyngeal mucositis, PD – pharyngeal dysphagia 
